Product
Gemcitabine/nab-Paclitaxel
1 clinical trial
1 indication
Indication
Resectable Pancreatic CancersClinical trial
Feasibility Study of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Intensity Modulated Radiotherapy in Resectable and Borderline Resectable Pancreatic CancerStatus: Completed, Estimated PCD: 2018-11-07